Genetic risk factors for chronic obstructive pulmonary disease

Current Opinion in Pulmonary Medicine

Volumn 8, Issue 2, 2002, Pages 87-94

  Sandford, Andrew J ^a   Joos, Ladina ^a   Paré, Peter D ^a  

^a ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; CYTOCHROME P450 1A1; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE; HEME OXYGENASE 1; INTERLEUKIN 1; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D BINDING PROTEIN;

ALLELE; ALPHA1 ANTITRYPSIN GENE; ANTIOXIDANT ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; DISEASE ASSOCIATION; FAMILIAL DISEASE; GENE ISOLATION; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC RISK; HEREDITY; HOMOZYGOSITY; HUMAN; INFLAMMATION; PATHOGENESIS; REVIEW; RISK FACTOR; TWINS; XENOBIOTIC METABOLISM;

EID: 0036171747     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200203000-00002     Document Type: Review

References (107)

1. Smoking and lung function
2. Household aggregation of pulmonary function and chronic bronchitis
3. Familial aggregation of chronic respiratory disease: Use of National Health Interview Survey data for specific hypothesis testing
4. A common familial component in lung cancer and chronic obstructive pulmonary disease
5. Studies of the familial aggregation of chronic bronchitis and obstructive airways disease
6. Genotypic and phenotypic similarities in pulmonary function among family members of adult monozygotic and dizygotic twins
7. Familial factors related to lung function in children aged 6-10 years: Results from the PAARC epidemiologic study
8. Family resemblance for normal pulmonary function
9. Genetic and environmental influences on pulmonary function in adult twins
10. Assessment of genetic and nongenetic influences on pulmonary function: A twin study
11. Segregation analysis of pulmonary function among families in the Framingham Study
12. Segregation analysis of two lung function indices in a random sample of young families: The Humboldt Family Study
13. Familial correlation and segregation analysis of forced expiratory volume in one second (FEV1), with and without smoking adjustments, in a Tucson population
14. The electrophoretic alpha1 -globulin pattern of serum in alpha1-antitrypsin deficiency
15. Pulmonary emphysema and α1-antitrypsin deficiency
16. Studies in α1-antitrypsin deficiency
17. Hereditary deficiency of α1-antitrypsin
18. The abnormality of the S variant of human alpha-1-antitrypsin
19. Amino acid substitution Glu leads to Lys alpha1-antitrypsin PiZ
20. Molecular abnormality of human alpha1-antitrypsin variant (Pi-ZZ) associated with plasma activity deficiency
21. Molecular basis of α1-antitrypsin deficiency
22. Clinical features and history of the destructive lung disease associated with α1-antitrypsin deficiency of adults with pulmonary symptoms
23. Smoking, lung function, and α1-antitrypsin deficiency
24. Neonatal screening for alpha1-antitrypsin deficiency
25. Survival of patients with severe α1-antitrypsin deficiency with special reference to non-index cases
26. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ)
27. α1-antitrypsin deficiency in nonsmokers
28. Variability of pulmonary function in alpha-1-antitrypsin deficiency: Clinical correlates
29. Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in alpha 1-antitrypsin deficiency
30. Clinical features of individuals with PISZ phenotype of a1-antitrypsin deficiency. α1-Antitrypsin Deficiency Registry Study Group
31. PISZ phenotype in chronic obstructive pulmonary disease
32. Heterozygosity in the Pi-system as a pathogenetic cofactor in chronic obstructive pulmonary disease (COPD)
33. α1-antitrypsin Pi types in COPD patients
34. a1-antitrypsin Pi-types in 965 COPD patients
35. Z and S mutations of the α1. antitrypsin gene and the risk of chronic obstructive pulmonary disease
36. Genetic risk factors for chronic obstructive pulmonary disease
37. Susceptibility genes for rapid decline of lung function in the Lung Health Study
38. Pi phenotypes and the prevalence of chest symptoms and lung function abnormalities in workers employed in dusty industries
39. Assessment of alpha-1-antitrypsin deficiency heterozygosity as a risk factor in the etiology of emphysema: Physiological comparison of adult normal and heterozygous protease inhibitor phenotype subjects from a random population
40. Pulmonary function in heterozygotes for α1-antitrypsin deficiency: A case-control study
41. Collaborative study to assess risk of lung disease in Pi MZ phenotype subjects
42. Risk of hospital admission for obstructive pulmonary disease in alpha(1)-antitrypsin heterozygotes of phenotype PiMZ
43. Molecular diagnosis of intermediate and severe alpha(1)-anfitrypsin deficiency: MZ individuals with chronic obstructive pulmonary disease may have lower lung function than MM individuals
44. Independent mutations in the flanking sequence of the α1-antitrypsin gene are associated with chronic obstructive airways disease
45. DNA polymorphisms of the α1-antitrypsin gene region in patients with chronic obstructive pulmonary disease
46. Mutation in the 3′ region of the α1-antitrypsin gene and chronic obstructive pulmonary disease
47. α1-antitrypsin Taq I polymorphism and a1-antichymotrypsin mutations in patients with obstructive pulmonary disease
48. Point mutation in a 3′ flanking sequence of the α1-antitrypsin gene associated with chronic respiratory disease occurs in a regulatory sequence
49. Mutation in an α1-antitrypsin enhancer results in an inteleukin-6 deficient acute-phase response due to loss of cooperativity between transcription factors
50. α1-Antitrypsin genotypes and the acute-phase response to open heart surgery
51. α1-Antitrypsin deficiency alleles and the Taq-I G->A allele in cystic fibrosis lung disease
52. α1-antitrypsin gene polymorphism related to respiratory system disease
53. Heterozygous α1-antichymotrypsin and PiZ a1-antitrypsin deficiency: Prevalence and clinical spectrum in asthmatic children
54. Mis-sense mutation of α1-antichymotrypsin gene associated with chronic lung disease
55. α1-antichymotrypsin mutations in patients with chronic obstructive pulmonary disease
56. Cloning of the human α2-macroglobulin gene and detection of mutations in two functional domains: The bait region and the thiolester site
57. Human microsomal epoxide hydrolase: Genetic polymorphism and functional expression in vitro of amino acid variants
58. Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: Studies with cisstilbene oxide, carbamazepine 10, 11-epoxide and naphthalene
59. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema
60. Microsomal epoxide hydrolase genotypes and chronic obstructive pulmonary disease in Japanese
61. Genetic susceptibility to chronic obstructive pulmonary disease in Koreans: Combined analysis of polymorphic genotypes for microsomal epoxide hydrolase and glutathione S-transferase M1 and T1
62. Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer
63. Peculiarities of the GSTM1 0/0 genotype in French heavy smokers with various types of chronic bronchitis
64. Heterogeneous expression and polymorphic genotype of glutathione S-transferases in human lung
65. Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons
66. Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease
67. Relationship between genotype and function of the human CYP1A1 gene
68. Association between the CYP1A1 gene polymorphism and susceptibility to emphysema and lung cancer
69. Protective effects of heme oxygenase-1 in acute lung injury
70. Heme oxygenase-1: Function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury
71. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema
72. d(TG)n.d(CA)n sequences upstream of the rat prolactin gene form Z-Dna and inhibit gene transcription
73. Gc-globulin (vitamin D-binding protein) enhances the neutrophil chemotactic activity of C5a and C5a des Arg
74. Vitamin D-binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocyte
75. Possible protective effect against chronic obstructive airways disease by the GC 2 allele
76. Vitamin D binding protein variants and the risk of COPD
77. Secretion of tumour necrosis factor a and lymphotoxin a in relation to polymorphisms in the TNF genes and HLA-DR alleles: Relevance for inflammatory bowel disease
78. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria
79. Tumour necrosis factor haplotypes and asthma
80. Prevalence of tumour necrosis factor-α and angiotensin converting enzyme polymorphisms in mild/moderate and fatal/near-fatal asthma
81. Tumor necrosis factor-α gene polymorphism in chronic bronchitis
82. Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease
83. Neither IL-1beta, IL-1 receptor antagonist, nor TNF-alpha polymorphisms are associated with susceptibility to COPD
84. Tumour necrosis factor-alpha gene promoter polymorphism in chronic obstructive pulmonary disease
85. Interleukin-1 receptor antagonist: Role in biology
86. The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14-q21, in the region of the IL-1 alpha and IL-1 beta loci
87. Single base polymorphism at -511 in the human interleukin-1 β gene (IL1 β)
88. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat
89. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist
90. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus
91. Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene
92. IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease
93. IL-1 receptor antagonist (IL-1RA) plasma levels are co-ordinately regulated by both IL-1RA and IL-1β genes
94. Association of IL1β and IL1 receptor antagonist haplotypes with rate of decline in lung function in smokers
95. Long-term lung clearance in humans studied with Teflon particles labeled with chromium-51
96. Tracheobronchial clearance in twins
97. Autonomic and airway reactivity in obligate heterozygotes for cystic fibrosis
98. Pulmonary abnormalities in obligate heterozygotes for cystic fibrosis
99. Sequence analysis of the cystic fibrosis gene in patients with disseminated bronchiectatic lung disease: Application in the identification of a cystic fibrosis patient with atypical clinical course
100. Sweat chloride and ΔF508 mutation, in chronic bronchitis or bronchiectasis
101. Abnormal distribution of cystic fibrosis ΔF508 allele in adults with chronic bronchial hypersecretion
102. CFTR gene variant IVS8-5T in disseminated bronchiectasis
103. Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease
104. CFTR gene mutations-including three novel nucleotide substitutions-and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease
105. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes: The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation
106. Disseminated bronchiectasis and cystic fibrosis gene mutations